# Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

Study · id `cardio:ct-nct03078907` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03078907](<https://clinicaltrials.gov/study/NCT03078907>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03078907

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

## Technical summary

Registry record NCT03078907. Randomized; quadruple masking; primary purpose other. Start 2017-11-08 (actual); primary completion 2020-02-10 (actual). Results posted on 2021-02-23.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose other
- Phase: Phase 4
- Enrolled: 108 participants (enrolled count; ClinicalTrials.gov record NCT03078907, source copy `cardio:ctgov-nct03078907-2025-03-30`, retrieved 2026-10-31)
- Started: 2017-11-08 (actual) (ClinicalTrials.gov record NCT03078907, source copy `cardio:ctgov-nct03078907-2025-03-30`, retrieved 2026-10-31)
- Primary completion: 2020-02-10 (actual) (ClinicalTrials.gov record NCT03078907, source copy `cardio:ctgov-nct03078907-2025-03-30`, retrieved 2026-10-31)
- Completion: 2020-02-10 (actual) (ClinicalTrials.gov record NCT03078907, source copy `cardio:ctgov-nct03078907-2025-03-30`, retrieved 2026-10-31)
- Results first posted: 2021-02-23 (ClinicalTrials.gov record NCT03078907, source copy `cardio:ctgov-nct03078907-2025-03-30`, retrieved 2026-10-31)
- Countries: United States; Austria; France; Germany; Ireland; Norway; Portugal; Sweden; Switzerland; United Kingdom (ClinicalTrials.gov record NCT03078907, source copy `cardio:ctgov-nct03078907-2025-03-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03078907-2025-03-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
- Acronym: TRACE
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Selexipag
- Intervention (Drug): Placebo
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE) (`cardio:pubmed-36089068`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cbe0ed907b67dbedbb020105a548f02eb958bf45ce71aa85c28461e8b9ffe116
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
